Hope from Naples: research promoted by researcher Pascale
(ANSA) – NAPLES, 18 SEPTEMBER – An important study on lung cancer is Neapolitan which, postponing the progression of the disease by six months, reduces the size of the tumor in 70 percent of patients, prolongs survival by 11 months and affects especially smokers and former smokers. The results presented this morning in Paris during the annual congress of the European Society of Medical Oncology (ESMO).
It is called Beverly and from the encounter of an “intelligent” drug already in use in current therapies, Erlotinib, and an antiangiogenic drug, ie that blocks the ability of the tumor to create its own blood vessels, Bevacizumab, postpones by about six disease progression and prolongs survival by nearly a year, reducing tumor size in 70 percent of patients, compared to 50 percent with erlotinib alone. The study designed, promoted and managed by Marilina Piccirillo, a young Pascale researcher, in collaboration with the Clinical Trials Unit of the Neapolitan IRCCS, directed by Franco Perrone, and the Toraco-Polmponare Oncology directed by Alessandro Morabito, was launched in 2016. on 160 patients enrolled. Of these patients, smokers and former smokers were the ones who benefited most from the combination of drugs. (HANDLE).
breaking latest news © Copyright ANSA
.